Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long Term Safety and Tolerability Study of Open-Label Liposomal Amikacin for Inhalation (ARIKACE™) in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa

NCT01316276 is registered in ClinicalTrials.gov with Insmed Incorporated as lead sponsor.

NCT NCT01316276
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01316276 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long Term Safety and Tolerability Study of Open-Label Liposomal Amikacin for Inhalation (ARIKACE™) in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa
Lead sponsor
Insmed Incorporated
Phase
Phase 3
Overall status
Completed
Start date
October 5, 2012
Completion date
July 16, 2015
Enrollment
206 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis